MEDICATION ON THE BASIS OF XENON, PREFERABLY IN COMBINATION WITH AN NMDA RECEPTOR ANTAGONIST, FOR FIGHTING THE NEUROGENERATIVE DISORDER PARKINSON'S DISEASE

摘要

The invention relates to a gaseous medication containing xenon, to be used by inhalation for treating, slowing or preventing neurological deterioration resulting from Parkinson's disease in a human patient. The medication preferably contains between 10 and 80% by volume xenon. The gaseous medication containing xenon is advantageously used in combination with at least one NMDA receptor antagonist such as memantine or nitromemantine, in liquid or solid form, in particular in the form of a tablet or gel capsule.